Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicorandil for primary coronary microvascular disease
ChiCTR1900022978Phase 4Not yet recruiting
- Sponsor
- Beijing Hospital
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of nicorandil in Coronary Small Vessel Disease (CMD) (2 arms), sponsored by Beijing Hospital. Primary endpoint: Scope of myocardial perfusion defect. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
nicorandil
03
Conditions
Coronary Small Vessel Disease (CMD)
Beyond the preview
Go deeper on ChiCTR1900022978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900022978.